12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GLYX-13: Phase IIa data

A double-blind, U.S. Phase IIa trial in 116 patients with HDRS-17 scores of >=21 units and who failed >=1 antidepressant during the current depressive episode showed that a single 10 mg/kg dose of IV GLYX-13 met the primary endpoint of improving HDRS-17 scores from baseline to 24 hours vs. placebo (p<0.05). Naurex said the significant improvement persisted for an average...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >